Maury Raycroft Analyst Performance

Equity Research Analyst, Biotechnology at Jefferies Financial Group

Maury Raycroft is a stock analyst at Jefferies Financial Group focused in the healthcare sector, covering 31 publicly traded companies. Over the past year, Maury Raycroft has issued 27 stock ratings, including strong buy, buy, and hold recommendations. While full access to Maury Raycroft's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Maury Raycroft's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
55 Last 9 Years
Buy Recommendations
81.48% 44 Buy Ratings
Companies Covered
31 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy3.7%2 ratings
Buy77.8%42 ratings
Hold18.5%10 ratings
Sell0.0%0 ratings

Out of 54 total stock ratings issued by Maury Raycroft at Jefferies Financial Group, the majority (77.8%) have been Buy recommendations, followed by 18.5% Hold and 3.7% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
96.8% of companies on NASDAQ
30 companies
NYSE
3.2% of companies on NYSE
1 company

Maury Raycroft, an analyst at Jefferies Financial Group, currently covers 31 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
30 companies
96.8%
Miscellaneous
1 company
3.2%

Maury Raycroft of Jefferies Financial Group specializes in stock coverage within the Healthcare sector, with additional focus on companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
25 companies
80.6%
PHARMACEUTICALS
4 companies
12.9%
Miscellaneous
1 company
3.2%
HEALTHCARE PROVIDERS & SERVICES
1 company
3.2%

Maury Raycroft's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
11/16/2026Initiated Coverage$16.98Strong-Buy
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
11/10/2026Reiterated Rating$24.49$65.00Buy
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
11/10/2026Initiated Coverage$18.67$32.00Buy
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
10/29/2026Reiterated Rating$3.81$10.00Buy
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
10/22/2026Initiated Coverage$8.37$25.00Buy
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
10/22/2026Initiated Coverage$8.38$25.00Buy
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
10/5/2026Upgrade$15.04Strong-Buy
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
9/28/2026Initiated Coverage$8.77$29.00Buy
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
9/28/2026Initiated Coverage$9.23$29.00Buy
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
9/10/2026Initiated Coverage$14.69$31.00Buy
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
9/3/2026Lower Price Target$14.85$28.00Buy
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
7/13/2026Boost Price Target$38.86$47.00Buy
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
6/25/2026Upgrade$30.14$60.00Buy
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
5/26/2026Initiated Coverage$25.89$39.00Buy
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
5/26/2026Initiated Coverage$27.84$39.00Buy
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
5/14/2026Downgrade$25.51$27.00Hold
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
5/12/2026Lower Price Target$11.43$33.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
3/16/2026Downgrade$313.41$330.00Hold
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
3/13/2026Reiterated Rating$5.67$19.00Buy
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3/9/2026Set Price Target$79.23$98.00Buy
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
3/5/2026Reiterated Rating$16.80$18.00Buy
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3/5/2026Reiterated Rating$5.53$9.00Buy
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2/3/2026Boost Price Target$31.02$43.00Buy
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
2/2/2026Boost Price Target$52.96$81.00Buy
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
12/30/2025Downgrade$0.29Hold
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
12/30/2025Lower Price Target$19.72$63.00Buy
Celcuity, Inc. stock logo
CELC
Celcuity
12/2/2025Boost Price Target$98.49$134.00Buy
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
11/7/2025Upgrade$13.95$21.00Buy
OPKO Health, Inc. stock logo
OPK
OPKO Health
10/30/2025Reiterated Rating$1.46$1.60Hold
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
10/30/2025Lower Price Target$449.56$549.00Buy
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
10/17/2025Downgrade$4.17$7.00Hold
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
9/22/2025Initiated Coverage$12.97$15.00Buy
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9/10/2025Set Price Target$27.31$35.00
Valneva SE Sponsored ADR stock logo
VALN
Valneva
8/25/2025Set Price Target$9.08$14.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
7/7/2025Boost Price Target$323.82$384.00Buy
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
6/24/2025Initiated Coverage$3.16$3.50Hold
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3/11/2025Lower Price Target$6.86$53.00Buy
Chimerix, Inc. stock logo
CMRX
Chimerix
3/5/2025Reiterated Rating$8.46$8.50Hold
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
2/10/2025Boost Price Target$3.90$8.00Buy